Indian pharmaceutical group Bharat Biotech said on Tuesday that it will “probably” export millions of its Covaxin vaccine to the United Arab Emirates and Brazil later this week.
Covaxin obtained regulatory clearance in India on January 3, despite a lack of data attesting to its safety and efficacy. Results of advanced trials with 25,800 participants will only be disclosed in March. Still, Indian regulators stand by their position, citing a test with 26 patients to say that the vaccine is effective against new variants of the coronavirus.
Bharat Biotech has filed for authorization to run phase 3 trials in Brazil, but a recent move by Brazilian health regulator Anvisa lifted the requirement for local trials to obtain emergency approval.
Support this coverage →
Search
